Sellas Leads Retail Traders' Bullish Poll With 50% of 3,400 Votes Overnight; Regal Trial Nears Key Milestone

According to a Stocktwits poll on July 7, Sellas Life Sciences (SLS) shares rose overnight as retail traders picked the biotech firm as their top bullish stock with 50% of 3,400 votes, compared to Ondas Holdings at 24%, ImmunityBio at 18%, and PayPal at 8%. Attention centers on the company's Phase 3 Regal trial of GPS in acute myeloid leukemia, which has reached 78 of the 80 events required for final analysis.

CEO Angelos Stergiou's Fourth of July LinkedIn post fueled acquisition speculation after he thanked "clinical investigators, research sites, collaborators, strategic partners, and shareholders" and stated he was "incredibly optimistic about the future." SLS stock surged 542% over the past year, with market capitalization climbing from $73 million at the start of 2024 to over $1.5 billion by mid-2026.